Drugs / GLR2007
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04444427 | Jul 2020 → Jul 2022 | glioblastoma, non-small cell lung carcinoma | Gan and Lee Pharmaceuticals, USA | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-04-06 | Gan and Lee Pharmaceuticals, USA | Regulatory Gan & Lee receives EMA orphan drug designation for Phase I drug candidate GLR2007 for the treatment of glioma. ganlee.com ↗
The EMA’s positive decision for GLR2007’s orphan drug designation is another milestone in the clinical development program as this compound was also recently granted ODD by the FDA |
| 2021-01-29 | Gan and Lee Pharmaceuticals, USA | Regulatory Phase 1 Drug Candidate GLR2007 Developed by Gan & Lee has been Granted Fast Track Designation by the U.S. FDA ganlee.com ↗
Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for GLR2007, for the treatment of patients with glioblastoma. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-04-06 | Gan and Lee Pharmaceuticals, USA | Gan & Lee receives EMA orphan drug designation for Phase I drug candidate GLR2007 for the treatment of glioma. ganlee.com ↗ |
| 2021-01-29 | Gan and Lee Pharmaceuticals, USA | Phase 1 Drug Candidate GLR2007 Developed by Gan & Lee has been Granted Fast Track Designation by the U.S. FDA ganlee.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLR2007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04444427 ↗ |
| Route | Oral | “Administered orally” NCT04444427 ↗ |